Sort   by:  
 Page size 
MetabolomicsCysteamine-bicalutamide combination therapy corrects proximal tubule phenotype in cystinosis
Nephropathic cystinosis is a severe monogenic kidney disorder caused by mutations in CTNS, encoding the lysosomal transporter cystinosin, resulting in lysosomal cystine accumulation. The sole treatment, cysteamine, slows down the disease progression, but does not correct the established renal proxim...
2021-06-24 | MTBLS2538 | MetaboLights
MetabolomicsFetal Metabolic Stress Disrupts Immune Homeostasis and Induces Proinflammatory Responses in Human Immunodeficiency Virus Type 1- and Combination Antiretroviral Therapy-Exposed Infants
Increased morbidity and fetal growth restriction are reported in uninfected children born to human immunodeficiency virus type 1 (HIV-1)–infected women treated with antiretroviral (ARV) therapy. Viruses and/or pharmacological interventions such as ARVs can induce metabolic stress, skewing the cell’s...
2018-06-06 | MTBLS449 | MetaboLights
MetabolomicsThe enhancing therapeutic effect of neonatal jaundice by bifidobacterium through regulating inflammation and gut microbiota in combination with phototherapy—a randomized controlled trial

Hyperbilirubinemia is one of the most common diseases in neonates, and phototherapy is currently the most commonly used treatment in medicine, but previous studies have found that phototherapy can lead to changes in the intestinal flora of jaundice neonates, especially bifidobacteria. The focus o...

2026-03-26 | MTBLS14123 | MetaboLights
GenomicsCombination therapies for personalized cancer medicine
It is the ambition of the team formed by members of the Netherlands Cancer Institute (NKI) and the Cancer Genome Project at the Wellcome Trust Sanger Institute (WTSI) to unravel the genomic and phenotypic complexity of human cancers in order to identify optimal drug combinations for personalized can...
EGAS00001000655 | EGA
TranscriptomicsTranscription profiling of brain hemispheres from R6/2 transgenic mice treated with a combination drug therapy (tacrine, moclobemide and creatine) to study the molecular impact of the drug therapy on Huntingtons disease.
Huntington's disease is a genetic disease caused by a single mutation. It is characterised by progressive movement, emotional and cognitive deficits. R6/2 transgenic mice carrying the Huntington's disease mutation have a progressive neurological phenotype, including deterioration in cognitive functi...
ORGANISM(S): Mus musculus 
2007-12-13 | E-GEOD-857 | biostudies-arrayexpress
ProteomicsThe Combination of Remdesivir and Ivermectin Exerts Highly Potent and Synergistic Antiviral Activity Against Murine Coronavirus and SARS-CoV-2 Infections
The COVID-19 pandemic highlighted the urgent need to develop effective and broad-spectrum antiviral therapies against coronaviruses. One strategy to address this concern is combination therapy using repurposed drugs against zoonotic viruses with pandemic potential. We previously demonstrated that th...
ORGANISM(S): Mus musculus (Mouse) Betacoronavirus 
2026-09-07 | PXD073706 | Pride
Remdesivir  ivermectin  combination therapy  repurposed drugs  murine hepatitis virus  proteomics  transcriptomics 
GenomicsIdentification of clinical combination therapies to induce durable responses in kidney cancers
Identification of clinical combination therapies to induce durable responses in kidney cancers
PRJNA719177 | ENA
GenomicsCombination therapies of porcupine inhibition with ruxolitinib, ibrutinib or belumosudil in murine sclerodermatous GvHD
Combination therapies of porcupine inhibition with ruxolitinib, ibrutinib or belumosudil in murine sclerodermatous GvHD
PRJNA1197368 | ENA
GenomicsSynergistic combination therapies involving regorafenib in experimental glioma based on genome-wide CRISPR-Cas9 functional screens
Synergistic combination therapies involving regorafenib in experimental glioma based on genome-wide CRISPR-Cas9 functional screens
PRJNA1138642 | ENA
ProteomicsResistance mechanism to Notch inhibition and combination therapy in human T cell acute lymphoblastic leukemia
Gain-of-function mutations in NOTCH1 are among the most frequent genetic alterations in T cell acute lymphoblastic leukemia (T-ALL), making the Notch signaling pathway a promising therapeutic target for personalized medicine. Yet, a major limitation for long-term success of targeted therapy is relap...
ORGANISM(S): Homo sapiens (Human) 
2024-01-26 | PXD038908 | Pride
Combination therapies Pik3r1 Notch1 Resistance mechanisms T-all 
Sort   by:  
 Page size